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Background
HIV infection increases the risk of adverse drug erup-
tions. The reason for this is unclear; the mechanism
probably involves drug specific cytotoxic lymphocytes.
The aim of the study was to observe the spectrum of
adverse cutaneous eruptions to nevirapine.
Methods
PLHIV initiated on nevirapine based ART regimens
between 2010 and 2011, were included in the cross sec-
tional study. These hospitalized patients were followed
up for the sequence of events. A detailed concomitant
drug history was taken to rule out other impending
drugs which can cause similar drug reactions.
Results
In this analysis, 80% were females, 70% heterosexuals,
20% homosexuals and 10% intravenous drug users.
Average age of patients was 31.70± 9.89 years. The spec-
trum of drug eruptions ranged from erythematous
maculopapular generalized rash in 20% of patients to
grade four SJS & TEN in 80%. Regression and inverse
growth model was employed to find out the significant
duration between the onset of nevirapine rash and
initiation of ART. Mean duration of onset of nevirapine
rash was 12.40±3.78 days, with mean CD4 count at the
time of drug reaction was 162.10±32.61 microns/dl. It
was observed that the correlation co-efficient (r=0.981)
between the onset of nevirapine rash and CD4 count
was significant (P≤0.05), which clearly depicts the asso-
ciation of the onset of nevirapine rash to low CD4
count (<200 microns/dL).
Conclusion
NVP rash can show polymorphic manifestations, and
the majority of them occurs within first 4-6 weeks of
initiation of ART and is often associated with low base-
line CD4 count.
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